Sign in
4

Changes in Ownership

RxSight, Inc. Filed Acc 0000950170-24-080522

Chief Financial Officer sold 18,402 shares at an average $58.68 ($1,079,816)

  • Chief Financial Officer acquired 10,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Thunen Shelley B Chief Financial Officer 2024-07-01 Option exercise 10b5-1 +10,000 $15.60 $155,983 23,938 D: show line 1 in the form
Thunen Shelley B Chief Financial Officer 2024-07-01 Sale 10b5-1 −8,146 $58.41 $475,785 15,792 D: show line 2 in the form
Thunen Shelley B Chief Financial Officer 2024-07-01 Sale 10b5-1 −1,854 $59.48 $110,270 13,938 D: show line 3 in the form
Thunen Shelley B Chief Financial Officer 2024-07-01 Sale 10b5-1 −6,599 $58.55 $386,366 1,803 I: show line 4 in the form
Thunen Shelley B Chief Financial Officer 2024-07-01 Sale 10b5-1 −1,803 $59.56 $107,394 0 I: show line 5 in the form
Open-market sales · 18,402 sh · avg $58.68 · $1,079,816

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Thunen Shelley B Chief Financial Officer 2024-07-01 Option exercise · Stock Option (right to buy) 10b5-1 −10,000 36,805 D: show line 6 in the form
Loading xslF345X05/ownership.xml…